Compare IMMP & THCH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | IMMP | THCH |
|---|---|---|
| Founded | 1987 | 2018 |
| Country | Australia | China |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Blank Checks |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 58.2M | 58.9M |
| IPO Year | 2012 | 2021 |
| Metric | IMMP | THCH |
|---|---|---|
| Price | $0.62 | $2.10 |
| Analyst Decision | Hold | |
| Analyst Count | 3 | 0 |
| Target Price | ★ $5.50 | N/A |
| AVG Volume (30 Days) | ★ 22.9M | 3.7K |
| Earning Date | 04-23-2026 | 04-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $445.09 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.29 | $1.69 |
| 52 Week High | $3.53 | $3.25 |
| Indicator | IMMP | THCH |
|---|---|---|
| Relative Strength Index (RSI) | 40.17 | 50.32 |
| Support Level | $0.29 | $2.09 |
| Resistance Level | $1.89 | $2.25 |
| Average True Range (ATR) | 0.08 | 0.11 |
| MACD | 0.12 | -0.00 |
| Stochastic Oscillator | 42.48 | 53.12 |
Immutep Ltd is a Phase three clinical biotechnology company developing novel Lymphocyte Activation Gene-3 (LAG-3) related immunotherapies for cancer and autoimmune disease. It has a diversified product portfolio that harnesses LAG-3's ability to stimulate the body's immune response to fight cancer or suppress the immune system to treat autoimmune disease. The company is focused on advancing its product candidate, eftilagimod alfa (efti), through its registrational Phase three clinical trial towards marketing approval in first-line non-small cell lung cancer (1L NSCLC). The other product candidates in its portfolio include TACTI-004, TACTI-003, AIPAC-003, TACTI-002, INSIGHT-005, and others, being developed as potential therapies for various cancers and autoimmune diseases.
TH International Ltd is the parent company of the franchise of Tim Hortons coffee shops and has the rights to operate Tim Hortons coffee shops in mainland China, Hong Kong, and Macau. Through the Tim Hortons brand, the firm offers freshly brewed coffee, tea, and other beverages, bakery & sides, and sandwiches. The Company operated under single reportable segment, Tim Hortons. The company's revenue is derived from its operations in the PRC.